Pyrazolones as therapeutics for kinase-mediated inflammatory disorders

Expert Opinion on Therapeutic Patents

Volumn 15, Issue 11, 2005, Pages 1617-1623

  Clark, Michael P ^a   Bookland, Roger G ^a  

^a PROCTER AND GAMBLE PHARMACEUTICALS   (United States)

Author keywords

Arthritis; ATP mimetic; Bicyclic pyrazolone; Inflammation; Kinase; p38 mitogen activated protein kinase (MAPK); Pyrazolone

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; ADENOSINE TRIPHOSPHATE; ANTIINFLAMMATORY AGENT; CYCLOOXYGENASE 2 INHIBITOR; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE P38 INHIBITOR; PHOSPHOTRANSFERASE INHIBITOR; PYRAZOLONE DERIVATIVE;

ACYLATION; ANTIINFLAMMATORY ACTIVITY; BINDING SITE; CHEMICAL INTERACTION; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENTERITIS; ENZYME INHIBITION; INFLAMMATORY DISEASE; NONHUMAN; OSTEOARTHRITIS; PROTEIN PHOSPHORYLATION; REVIEW; RHEUMATOID ARTHRITIS; STRUCTURE ANALYSIS;

EID: 27944486177     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.15.11.1617     Document Type: Review

References (20)

1. MANNING G, WHYTE DB, MARTINEZ R, HUNTER T, SUDARSANAM S: The protein kinase complement of the human genome. Science (2002) 298:1912-1934.
2. CHERRY M, WILLIAMS DH: Recent kinase and kinase inhibitor X-ray structures: mechanisms of inhibition and selectivity insights. Curr. Med. Chem. (2004) 11:663-673.
3. PARGELLIS C, REGAN J: Inhibitors of p38 mitogen-activated protein kinase for the treatment of rheumatoid arthritis. Curr. Opin. Investig. Drugs (2003) 4(5):566-571.
4. BRENNAN FM, FELDMAN M: Cytokines in autoimmunity. Curr. Opin. Immunol. (1996) 8:872-877.
5. BAUGH JA, BUCALA R: Mechanisms for modulating TNF-α in immune and inflammatory disease. Curr. Opin. Drug Discov. Dev. (2001) 4(5):635-650.
6. PALLADINO MA, BAHJAT FR, THEODORAKIS EA, MOLDAWER LL: Anti-TNF-α therapies: the next generation. Nat. Rev. Drug Discov. (2003) 2:736-746.
7. GALLAGHER TF, FIER-THOMPSON SM, GARIGIPATI RS et al.: 2,45-Triarylimidazole inhibitors of IL-1 biosynthesis. Bioorg. Med. Chem. Lett. (1995) 5:1171-1174.
8. ADAMS JL, BOEHM JC, KASSIS S et al.: Pyrimidinylimidazole inhibitors of CSBP/p38 kinase demonstrating decreased inhibition of hepatic cytochrome p450 enzymes. Bioorg. Med. Chem. Lett. (1998) 8:3111-3116.
9. ADAMS JL, BADGER AM, KUMAR S, LEE JC: p38 MAP kinase: molecular target for the inhibition of pro-inflammatory cytokines. In: Progress in Medicinal Chemistry. King FD, Oxford AW (Eds), Elsevier Science BV (2001):1-60.
10. TREJO AT, ARZENO H, BROWNER M et al.: Design and synthesis of 4-azaindoles as inhibitors of p38 MAP Kinase. J. Med. Chem. (2003) 46(22):4702-4713.
11. TAMAYO N, LIAO L, GOLDBERG M et al.: Design and synthesis of potent pyridazine inhibitors of p38 map kinase. Bioorg. Med. Chem. Lett. (2005) 15(9):2409-2413.
12. LIVERTON NJ, BUTCHER JW, CLAIBORNE CF et al.: Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase. J. Med. Chem. (1999) 42:2180-2190.
13. LAUGHLIN SK, CLARK MP, DJUNG JF et al.: The development of new isoxazolone based inhibitors of tumor necrosis factor-α (TNF-α) production. Bioorg. Med. Chem. Lett. (2005) 15:2399-2403.
14. CLARK MP, LAUGHLIN SK, LAUFERSWEILER MJ et al.: Development of orally bioavailable bicyclic pyrazolones as inhibitors of tumor necrosis factor-α production. J. Med. Chem. (2004) 47(11):2724-2727.
15. GOLEBIOWSKI A, TOWNES JA, LAUFERSWEILER MJ et al.: The development of monocyclic pyrazolone based cytokine synthesis inhibitors. Bioorg. Med. Chem. Lett. (2005) 15:2285-2289.
16. LAUFERSWEILER MJ, BRUGEL TA, CLARK MP et al.: The development of novel inhibitors of tumor necrosis factor-α (TNF-α) production based on substituted[5,5]-bicyclic pyrazolones. Bioorg. Med. Chem. Lett. (2004) 14:4267-4272.
17. TOWNES JA, GOLEBIOWSKI A, CLARK MP et al.: The development of bicyclic pyrazole based cytokine synthesis inhibitors. Bioorg. Med. Chem. Lett. (2005) 15:2285-2289.
18. DE LASZLO SE, VISCO D, AGARWAL L, CHANG L, O'KEEFE SJ: Pyrroles and other heterocycles as inhibitors of p38 kinase. Bioorg. Med. Chem. Lett. (1998) 8.2689-2694.
19. DE DIOS A, SHIH C, DE URALDE BL et al.: Design of potent and selective 2-aminobenzimidazole-based p38α MAP kinase inhibitors with excellent in vivo Efficacy. J. Med. Chem. (2005) 48(7):2270-2273.
20. ADAMS JL, VEAL J, SHEWCHUK L: Kinases. In: Protein Crystallography in Drug Discovery. Babine RE, Abdel-Meguid SS (Eds), Wiley-VCH Verlag GmbH & Co., Weinhem, Germany (2004):47-81.